The "Fast Money" traders give their final trades of the day.» Read More
Not even big layoffs can convince investors that companies are shoring up their balance sheet and are a safe place to put money.
I need a break from blogging all-things Pfizer. Sequenom to the rescue with more data on its diagnostic test for Down Syndrome. Out of nearly 900 women there were no false negatives, but for the first time SQNM reported one false positive.
More companies announced layoffs on Thursday as the employment picture continued to dim.
Stocks rose on Wednesday, capping the S&P 500's longest winning streak since November...
The editorial board of "The Wall Street Journal" weighs in today on the Pfizer-Wyeth deal. The opinion piece details all of the well-documented problems facing big pharma and—perhaps not surprisingly coming from the WSJ editorial page—blames Washington for many of them.
Reporters could only listen to Pfizer's hastily-organized "Investor Luncheon," so I can't tell you how many people showed up or what the room looked like. But Chairman and CEO Jeff Kindler drew a pretty good picture at the start of his opening remarks.
More companies announced layoffs on Tuesday as the employment picture continued to dim.
This is the first paragraph/short story.
Investors can’t help but wonder what’s the best way to play Pharma after Pfizer said it would buy rival Wyeth for $60 billion, a 20% premium!
The Dow rose in choppy trade on Monday, with investors shrugging off a grim warning about the year ahead from Caterpillar.
Major indexes finished higher after a yo-yo session Monday, with banks ending mixed after several attempts at a rally.
Wondering how the market could possibly be trading higher in the face of an incredibly dire warning from Caterpillar and another round of monster job cuts?
Stocks rallied, led by banks, after a wobbly open Monday. The market also got a boost from a blockbuster pharma deal, which helped overshadow a gloomy outlook from Caterpillar and other earnings worries.
As I've blogged before, it seems all of the major drug companies are falling all over each other to be the biggest, or at least the best "biopharma" firm in the world. But PFE and WYE are the first, as far as I know, to put it into a URL.
Stocks got a boost from a better-than-expected report on the housing market, which overshadowed Caterpillar's gloomy outlook and other earnings worries.
Another round of layoffs was announced by big-name companies Monday, adding to the gloom over rising unemployment.
Caterpillar posted fourth-quarter profit of $661 million, or $1.08 per share Monday morning, compared to $975 million or $1.50 per share in the prior year period. CAT, which also says it is will offer buyouts to 25,000 employees, dropped more than 8 percent five minutes after the open. Here's how I'm playing it!
Stock index futures pointed to a dip at the opening, despite a mega-deal brewing in the pharmaceutical sector.
Who's next in the potential wave of consolidation set off by Pfizer and Wyeth? Cramer has an idea.
Movement in a few key sectors could give stocks a much-needed boost.